1
|
Guerrero-Molina MP, Bernabeu-Sanz Á, Ramos-González A, Morales-Conejo M, Delmiro A, Domínguez-González C, Arenas J, Martín MA, González de la Aleja J. Magnetic resonance spectroscopy in MELAS syndrome: correlation with CSF and plasma metabolite levels and change after glutamine supplementation. Neuroradiology 2024; 66:389-398. [PMID: 38114794 DOI: 10.1007/s00234-023-03263-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 12/02/2023] [Indexed: 12/21/2023]
Abstract
PURPOSE MELAS syndrome is a genetic disorder caused by mitochondrial DNA mutations. We previously described that MELAS patients had increased CSF glutamate and decreased CSF glutamine levels and that oral glutamine supplementation restores these values. Proton magnetic resonance spectroscopy (1H-MRS) allows the in vivo evaluation of brain metabolism. We aimed to compare 1H-MRS of MELAS patients with controls, the 1H-MRS after glutamine supplementation in the MELAS group, and investigate the association between 1H-MRS and CSF lactate, glutamate, and glutamine levels. METHODS We conducted an observational case-control study and an open-label, single-cohort study with single-voxel MRS (TE 144/35 ms). We assessed the brain metabolism changes in the prefrontal (PFC) and parieto-occipital) cortex (POC) after oral glutamine supplementation in MELAS patients. MR spectra were analyzed with jMRUI software. RESULTS Nine patients with MELAS syndrome (35.8 ± 3.2 years) and nine sex- and age-matched controls were recruited. Lactate/creatine levels were increased in MELAS patients in both PFC and POC (0.40 ± 0.05 vs. 0, p < 0.001; 0.32 ± 0.03 vs. 0, p < 0.001, respectively). No differences were observed between groups in glutamate and glutamine (Glx/creatine), either in PFC (p = 0.930) or POC (p = 0.310). No differences were observed after glutamine supplementation. A positive correlation was found between CSF lactate and lactate/creatine only in POC (0.85, p = 0.003). CONCLUSION No significant metabolite changes were observed in the brains of MELAS patients after glutamine supplementation. While we found a positive correlation between lactate levels in CSF and 1H-MRS in MELAS patients, we could not monitor treatment response over short periods with this tool. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04948138; initial release 24/06/2021; first patient enrolled on 1/07/2021. https://clinicaltrials.gov/ct2/show/NCT04948138.
Collapse
Affiliation(s)
- María Paz Guerrero-Molina
- Neurology Department, Neuromuscular Disorders Unit, University Hospital, 12 de Octubre Avda. de Córdoba, S/N 28041, Madrid, Spain.
| | | | - Ana Ramos-González
- Department of Neuroradiology, University Hospital, 12 de Octubre, Madrid, Spain
| | - Montserrat Morales-Conejo
- Department of Internal Medicine, University Hospital, 12 de Octubre, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| | - Aitor Delmiro
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital, 12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Cristina Domínguez-González
- Neurology Department, Neuromuscular Disorders Unit, University Hospital, 12 de Octubre Avda. de Córdoba, S/N 28041, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Joaquín Arenas
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital, 12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Miguel A Martín
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital, 12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Jesús González de la Aleja
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
- Neurology Department, Epilepsy Unit, University Hospital, 12 de Octubre, Madrid, Spain
| |
Collapse
|
2
|
Fernández de la Torre M, Fiuza-Luces C, Laine-Menéndez S, Delmiro A, Arenas J, Martín MÁ, Lucia A, Morán M. Pathophysiology of Cerebellar Degeneration in Mitochondrial Disorders: Insights from the Harlequin Mouse. Int J Mol Sci 2023; 24:10973. [PMID: 37446148 DOI: 10.3390/ijms241310973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 06/22/2023] [Accepted: 06/28/2023] [Indexed: 07/15/2023] Open
Abstract
By means of a proteomic approach, we assessed the pathways involved in cerebellar neurodegeneration in a mouse model (Harlequin, Hq) of mitochondrial disorder. A differential proteomic profile study (iTRAQ) was performed in cerebellum homogenates of male Hq and wild-type (WT) mice 8 weeks after the onset of clear symptoms of ataxia in the Hq mice (aged 5.2 ± 0.2 and 5.3 ± 0.1 months for WT and Hq, respectively), followed by a biochemical validation of the most relevant changes. Additional groups of 2-, 3- and 6-month-old WT and Hq mice were analyzed to assess the disease progression on the proteins altered in the proteomic study. The proteomic analysis showed that beyond the expected deregulation of oxidative phosphorylation, the cerebellum of Hq mice showed a marked astroglial activation together with alterations in Ca2+ homeostasis and neurotransmission, with an up- and downregulation of GABAergic and glutamatergic neurotransmission, respectively, and the downregulation of cerebellar "long-term depression", a synaptic plasticity phenomenon that is a major player in the error-driven learning that occurs in the cerebellar cortex. Our study provides novel insights into the mechanisms associated with cerebellar degeneration in the Hq mouse model, including a complex deregulation of neuroinflammation, oxidative phosphorylation and glutamate, GABA and amino acids' metabolism.
Collapse
Affiliation(s)
- Miguel Fernández de la Torre
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
| | - Carmen Fiuza-Luces
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
| | - Sara Laine-Menéndez
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
| | - Aitor Delmiro
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, 28029 Madrid, Spain
- Servicio de Bioquímica Clínica, Hospital Universitario "12 de Octubre", 28041 Madrid, Spain
| | - Joaquín Arenas
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, 28029 Madrid, Spain
| | - Miguel Ángel Martín
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, 28029 Madrid, Spain
- Servicio de Genética, Hospital Universitario "12 de Octubre", 28041 Madrid, Spain
| | - Alejandro Lucia
- Faculty of Sports Sciences, European University of Madrid, 28670 Madrid, Spain
- Spanish Network for Biomedical Research in Fragility and Healthy Aging (CIBERFES), 28029 Madrid, Spain
| | - María Morán
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), 28041 Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, 28029 Madrid, Spain
| |
Collapse
|
3
|
Guerrero-Molina MP, Morales-Conejo M, Delmiro A, Morán M, Domínguez-González C, Arranz-Canales E, Ramos-González A, Arenas J, Martín MA, de la Aleja JG. High-dose oral glutamine supplementation reduces elevated glutamate levels in cerebrospinal fluid in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome. Eur J Neurol 2023; 30:538-547. [PMID: 36334048 DOI: 10.1111/ene.15626] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 10/07/2022] [Accepted: 10/27/2022] [Indexed: 11/08/2022]
Abstract
BACKGROUND AND PURPOSE Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder caused by mitochondrial DNA mutations. There are no disease-modifying therapies, and treatment remains mainly supportive. It has been shown previously that patients with MELAS syndrome have significantly increased cerebrospinal fluid (CSF) glutamate and significantly decreased CSF glutamine levels compared to controls. Glutamine has many metabolic fates in neurons and astrocytes, and the glutamate-glutamine cycle couples with many metabolic pathways depending on cellular requirements. The aim was to compare CSF glutamate and glutamine levels before and after dietary glutamine supplementation. It is postulated that high-dose oral glutamine supplementation could reduce the increase in glutamate levels. METHOD This open-label, single-cohort study determined the safety and changes in glutamate and glutamine levels in CSF after 12 weeks of oral glutamine supplementation. RESULTS Nine adult patients with MELAS syndrome (66.7% females, mean age 35.8 ± 3.2 years) were included. After glutamine supplementation, CSF glutamate levels were significantly reduced (9.77 ± 1.21 vs. 18.48 ± 1.34 μmol/l, p < 0.001) and CSF glutamine levels were significantly increased (433.66 ± 15.31 vs. 336.31 ± 12.92 μmol/l, p = 0.002). A side effect observed in four of nine patients was a mild sensation of satiety. One patient developed mild and transient elevation of transaminases, and another patient was admitted for an epileptic status without stroke-like episode. DISCUSSION This study demonstrates that high-dose oral glutamine supplementation significantly reduces CSF glutamate and increases CSF glutamine levels in patients with MELAS syndrome. These findings may have potential therapeutic implications in these patients. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov Identifier: NCT04948138. Initial release 24 June 2021, first patient enrolled 1 July 2021. https://clinicaltrials.gov/ct2/show/NCT04948138.
Collapse
Affiliation(s)
| | - Montserrat Morales-Conejo
- Department of Internal Medicine, University Hospital, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) and European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
| | - Aitor Delmiro
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - María Morán
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Cristina Domínguez-González
- Neurology Department, Neuromuscular Disorders Unit, University Hospital, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Elena Arranz-Canales
- Department of Internal Medicine, University Hospital, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) and European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, Madrid, Spain
| | | | - Joaquín Arenas
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Miguel A Martín
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Jesús González de la Aleja
- National Reference Center for Congenital Errors of Metabolism (CSUR) and European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, Madrid, Spain
- Neurology Department, Epilepsy Unit, University Hospital, Madrid, Spain
| |
Collapse
|
4
|
Guerrero-Molina MP, Morales-Conejo M, Delmiro A, Morán M, Domínguez-González C, Arranz-Canales E, Ramos-González A, Arenas J, Martín MA, González de la Aleja J. Elevated glutamate and decreased glutamine levels in the cerebrospinal fluid of patients with MELAS syndrome. J Neurol 2022; 269:3238-3248. [PMID: 35088140 PMCID: PMC8794606 DOI: 10.1007/s00415-021-10942-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 11/22/2022]
Abstract
Background Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder caused by mitochondrial DNA (mtDNA) mutations in the MT-TL1 gene. The pathophysiology of neurological manifestations is still unclear, but neuronal hyperexcitability and neuron–astrocyte uncoupling have been suggested. Glutamatergic neurotransmission is linked to glucose oxidation and mitochondrial metabolism in astrocytes and neurons. Given the relevance of neuron–astrocyte metabolic coupling and astrocyte function regulating energetic metabolism, we aimed to assess glutamate and glutamine CSF levels in MELAS patients. Methods This prospective observational case–control study determined glutamate and glutamine CSF levels in patients with MELAS syndrome and compared them with controls. The plasma and CSF levels of the remaining amino acids and lactate were also determined. Results Nine adult patients with MELAS syndrome (66.7% females mean age 35.8 ± 3.2 years) and 19 controls (63.2% females mean age 42.7 ± 3.8 years) were included. The CSF glutamate levels were significantly higher in patients with MELAS than in controls (18.48 ± 1.34 vs. 5.31 ± 1.09 μmol/L, p < 0.001). Significantly lower glutamine concentrations in patients with MELAS than controls were shown in CSF (336.31 ± 12.92 vs. 407.06 ± 15.74 μmol/L, p = 0.017). Moreover, the CSF levels of alanine, the branched-chain amino acids (BCAAs) and lactate were significantly higher in patients with MELAS. Conclusions Our results suggest the glutamate–glutamine cycle is altered probably due to metabolic imbalance, and as a result, the lactate–alanine and BCAA–glutamate cycles are upregulated. These findings might have therapeutic implications in MELAS syndrome. Supplementary Information The online version contains supplementary material available at 10.1007/s00415-021-10942-7.
Collapse
Affiliation(s)
- María Paz Guerrero-Molina
- Neuromuscular Disorders Unit, Neurology Department, University Hospital, 12 de Octubre, Madrid, Spain.
| | - Montserrat Morales-Conejo
- Department of Internal Medicine, University Hospital, 12 de Octubre, Madrid, Spain.,National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| | - Aitor Delmiro
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - María Morán
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Cristina Domínguez-González
- Neuromuscular Disorders Unit, Neurology Department, University Hospital, 12 de Octubre, Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Elena Arranz-Canales
- Department of Internal Medicine, University Hospital, 12 de Octubre, Madrid, Spain.,National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
| | - Ana Ramos-González
- Department of Neuroradiology, University Hospital, 12 de Octubre, Madrid, Spain
| | - Joaquín Arenas
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Miguel A Martín
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Jesús González de la Aleja
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain.,Epilepsy Unit, Neurology Department, University Hospital, 12 de Octubre, Madrid, Spain
| |
Collapse
|
5
|
Luque J, Mendes I, Gómez B, Morte B, Heredia ML, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Pérez‐Jurado LA, Montoliu L, Carracedo Á, Millán JM, Webb SM, Palau F, Lapunzina P, Aguado C, Aguado C, Albiñana V, Alías L, Almoguera B, Alonso J, Alonso‐Ferreira V, Alvarez‐Mora MI, Alvarez‐Mora MI, Antiñolo G, Arbones ML, Arenas J, Arjona E, Armangue T, Armstrong J, Arnedo M, Artuch R, Masó AA, Avila‐Fernandez A, Ayuso C, Badell I, Badenas C, Baeza ML, Baiget M, Balcells S, Ballesta‐Martínez MJ, Barahona M, Barros F, Bartoccioni PC, Bayona‐Bafaluy MP, Sanz SB, Bernabéu C, Bernal S, Blanco‐Kelly F, Blázquez A, Bodoy S, Bogliolo M, Borralleras C, Borrego S, Botella LM, Pieri FB, Bovolenta P, Bravo‐Gil N, Brea A, Bueno‐Lozano G, Bueren J, Bustamante A, Caballero T, Camacho‐Macorra C, Cámara Y, Camats‐Tarruella N, Barrio ÁC, Campuzano V, Cantarero L, Cantó J, Caparrós‐Martín JA, Cardellach F, Carmona R, Carracedo Á, Carretero M, Casado M, Casado JA, Casasnovas C, Cascón A, Casino P, Castaño L, Castilla‐Vallmanya L, Catala A, Cayuela ML, Cediel R, Cervera J, Codina‐Solà M, Contreras J, Cormand B, Corominas R, Corral J, Corrochano V, Cortés‐Rodríguez A, Corton M, Costa‐Roger M, Cozar M, Crespo I, Crispi F, Cruz R, Cuezva JM, Cuscó I, Dalmau J, Cima S, Luna S, De Luna N, Oyarzabal Sanz A, Campo M, Castillo I, Molina LDP, Pozo ÁD, Río M, Delmiro A, Desviat LR, Dierssen M, Domínguez‐González C, Domínguez‐Ruiz M, Dopazo J, Errasti E, Escámez MJ, Estañ MC, Esteban J, Estévez R, Ezquieta B, Fernández L, Fernández A, Fernández‐Cancio M, Fernàndez‐Castillo N, Jose PF, Fillat C, Fons C, Fort J, Fourcade S, Fraga MF, Gallano P, Gallardo E, García M, García‐Arumí E, García‐Bravo M, García‐Cazorla A, García‐Consuegra I, Garcia‐Garcia FJ, García‐García G, García‐Giménez JL, Garcia‐Gimeno MA, García‐Miñaur S, García‐Redondo A, García‐Silva MT, García‐Villoria J, Santiago FG, Garrabou G, Garrido G, Garrido‐Pérez N, Gaztambide S, Gil‐Campos M, Giroud‐Gerbetant J, Glover G, Gómez B, Gómez‐Puertas P, Gonzalez‐Cabo P, Gonzalez‐Casacuberta I, Pozo MG, González‐Quereda L, González‐Quintana A, Gort L, Gougeard N, Gratacos E, Grau JM, Grinberg D, Güenechea G, Guerrero R, Guillén‐Navarro E, Guitart‐Mampel M, Gutiérrez‐Arumí A, Heath K, Heredia M, Hernández‐Chico C, Herreras E, Hoenicka J, Homs A, Jimenez‐Estrada JA, Jimenez‐Mallebrera C, Jou C, Juarez‐Flores DL, Lapunzina P, Larcher F, Lasa A, Lassaletta L, Latorre‐Pellicer A, Linares D, Llacer JL, Llames S, Lopez‐Gallardo E, López‐Laso E, López‐Lera A, Lopez‐Lopez D, López‐Sánchez M, Heredia ML, Granados EL, Lorda‐Sanchez I, Lozano ML, Luque J, Madrigal I, García CM, Mansilla E, Marco‐Marín C, Marfany G, Marina A, Martí R, Martí S, Martin Y, Martín MA, Martín‐Hernandez E, Martin‐Merida I, Martínez R, Martínez‐Azorín F, Martinez‐Delgado B, Martínez‐Gil N, Martínez‐Glez VM, Martínez‐Momblán MA, Martínez‐Romero MC, Fernández PM, Santamaría LM, Martorell L, Meade P, Meana Á, Medina MÁ, Mendes I, Méndez‐Vidal C, Millán JM, Minguez P, Minguillón J, Mirra S, Molla B, Moltó E, Montero R, Montoliu L, Montoya J, Morán M, Moren C, Moreno M, Moreno JC, Moreno‐Galdó A, Moreno‐Pelayo MÁ, Mori MA, Morin M, Morte B, Mulero V, Muñoz‐Pujol G, Murillas R, Murillo‐Cuesta S, Nascimento A, Navarro S, Navas P, Nevado J, Nicolas A, Nieto MÁ, O’Callaghan M, Olavarrieta L, Ormazabal A, Ortiz‐Romero P, Osorio A, Páez D, Palacín M, Palacios‐Verdú MG, Palau F, Palencia‐Campos A, Pallardó FV, Palomares M, Peña‐Chilet M, Pérez B, Perez‐Florido J, Pérez‐García D, Perez‐Jimenez E, Pérez‐Jurado LA, Perkins JR, Perona R, Pie J, Pinós T, Pinto S, Potrony M, Puig S, Puig‐Butille JA, Puisac B, Pujol R, Pujol A, Quintana Ó, Rabionet R, Ramos FJ, Ranea JAG, Reina‐Castillón J, Resmini E, Ribes A, Rica I, Richard E, Riera P, Río P, Riveiro‐Alvarez R, Rivera J, Rivera‐Barahona A, Robledo M, Rodriguez‐Aguilera JC, Rosa LR, Rodríguez‐Palmero A, Rodriguez‐Pombo P, Rodriguez‐Revenga L, Rodríguez‐Santiago B, Rodríguez‐Sureda V, Alba MR, Cordoba SR, Romá‐Mateo C, Rubio V, Ruiz Á, Ruiz M, Ruiz‐Arenas C, Ruiz‐Perez VL, Ruiz‐Pesini E, Ruiz‐Ponte C, Rullo J, Sabater L, Salazar J, Salido E, Sanchez‐Jimeno C, Cuesta AMS, Soler MJS, Santacatterina F, Santamarina M, Santos A, Santos‐Ocaña C, Simarro FS, Sanz P, Sastre L, Schlüter A, Segovia JC, Segura‐Puimedon M, Seoane P, Serra‐Juhe C, Serrano M, Serratosa JM, Sevilla T, Surrallés J, Tahsin‐Swafiri S, Tell‐Martí G, Tenorio‐Castaño JA, Tizzano E, Tobias E, Tort F, Trujillano L, Trujillo‐Tiebas MJ, Ugalde C, Ugarteburu O, Urreizti R, Urrutia I, Valencia M, Vallcorba P, Vallespín E, Varela‐Nieto I, Vega A, Vélez‐Santamaria V, Vílchez JJ, Villa O, Villamar M, Webb SM, Zubeldia JM, Zurita O. CIBERER: Spanish National Network for Research on Rare Diseases: a highly productive collaborative initiative. Clin Genet 2022; 101:481-493. [PMID: 35060122 PMCID: PMC9305285 DOI: 10.1111/cge.14113] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 01/13/2022] [Accepted: 01/13/2022] [Indexed: 11/30/2022]
Abstract
CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low‐prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15‐year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research.
Collapse
Affiliation(s)
- Juan Luque
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Ingrid Mendes
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Beatriz Gómez
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Beatriz Morte
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Miguel López Heredia
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Enrique Herreras
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Virginia Corrochano
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Juan Bueren
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS‐FJD), Madrid Spain
| | - Pía Gallano
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Genetics Department, Hospital de la Santa Creu i Sant Pau Barcelona Spain
- Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona Spain
- Universitat Autònoma de Barcelona Barcelona Spain
| | - Rafael Artuch
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu Barcelona Spain
| | - Cristina Fillat
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona Spain
- Universitat de Barcelona Barcelona Spain
| | - Luis A. Pérez‐Jurado
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Experimental and Health Sciences Universitat Pompeu Fabra (UPF), Barcelona Spain
- Genetics Service, Hospital del Mar Barcelona Spain
- Hospital del Mar Research Institute (IMIM), Barcelona Spain
| | - Lluis Montoliu
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Molecular and Cellular Biology, National Centre for Biotechnology (CNB‐CSIC), Madrid Spain
| | - Ángel Carracedo
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Grupo de Medicina Xenómica, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela Santiago de Compostela Spain
- Fundación Pública Galega de Medicina Xenómica (SERGAS), IDIS Santiago de Compostela Spain
| | - José M. Millán
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Unidad de Genética, Hospital Universitario y Politécnico La Fe Valencia Spain
- Biomedicina Molecular Celular y Genómica, Instituto Investigación Sanitaria La Fe Valencia Spain
| | - Susan M. Webb
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Hospital S Pau, Dept Medicine/Endocrinology, IIB‐Sant Pau, Research Center for Pituitary Diseases Barcelona Spain
- Departamento de Medicina Universitat Autònoma de Barcelona Barcelona Spain
| | - Francesc Palau
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Genetic and Molecular Medicine, Hospital Sant Joan de Deu Barcelona Spain
- Laboratory of Neurogenetics and Molecular Medicine ‐ IPER, Institut de Recerca Sant Joan de Déu Barcelona Spain
- Institute of Medicine & Dermatology, Hospital Clínic Barcelona Spain
- Division of Pediatrics University of Barcelona School of Medicine Barcelona Spain
| | - Pablo Lapunzina
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- INGEMM‐Instituto de Genética Médica y Molecular, Hospital Universitario La Paz Madrid Spain
- Instituto de Investigación Sanitaria Hospital La Paz (IdiPAZ), Madrid Spain
- ERN‐ITHACA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Domínguez-González C, Laine-Menéndez S, Delmiro A, García-Consuegra I, Fernández-de la Torre M, Hernández-Laín A, Sayas J, de Fuenmayor C, Martin M, Morán M. MITOCHONDRIAL DISEASES. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Eguiburu-Jaime JL, Delmiro A, Lalueza A, Valenzuela PL, Aguado JM, Lumbreras C, Arenas J, Martín MA, Lucia A, López-Jiménez EA. Soluble fms-like tyrosine kinase-1: a potential early predictor of respiratory failure in COVID-19 patients. Clin Chem Lab Med 2021; 59:e289-e292. [PMID: 33606924 DOI: 10.1515/cclm-2021-0126] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 02/04/2021] [Indexed: 11/15/2022]
Affiliation(s)
| | - Aitor Delmiro
- Clinical Biochemistry Department, Hospital 12 de Octubre, Madrid, Spain
| | - Antonio Lalueza
- Internal Medicine Department, Hospital 12 de Octubre, Madrid, Spain
- Department of Medicine, School of Medicine, Complutense University, Madrid, Spain
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | | | - José M Aguado
- Department of Medicine, School of Medicine, Complutense University, Madrid, Spain
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
- Infectious Diseases Unit, University Hospital 12 de Octubre, Madrid, Spain
| | - Carlos Lumbreras
- Internal Medicine Department, Hospital 12 de Octubre, Madrid, Spain
- Department of Medicine, School of Medicine, Complutense University, Madrid, Spain
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - Joaquín Arenas
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - Miguel A Martín
- Clinical Biochemistry Department, Hospital 12 de Octubre, Madrid, Spain
- Infectious Diseases Unit, University Hospital 12 de Octubre, Madrid, Spain
| | - Alejandro Lucia
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
- Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain
| | | |
Collapse
|
8
|
Peralta S, González-Quintana A, Ybarra M, Delmiro A, Pérez-Pérez R, Docampo J, Arenas J, Blázquez A, Ugalde C, Martín MA. Novel ATAD3A recessive mutation associated to fatal cerebellar hypoplasia with multiorgan involvement and mitochondrial structural abnormalities. Mol Genet Metab 2019; 128:452-462. [PMID: 31727539 DOI: 10.1016/j.ymgme.2019.10.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 10/29/2019] [Accepted: 10/30/2019] [Indexed: 11/24/2022]
Abstract
Lethal neonatal encephalopathies are heterogeneous congenital disorders that can be caused by mitochondrial dysfunction. Biallelic large deletions in the contiguous ATAD3B and ATAD3A genes, encoding mitochondrial inner membrane ATPases of unknown function, as well as compound heterozygous nonsense and missense mutations in the ATAD3A gene have been recently associated with fatal neonatal cerebellar hypoplasia. In this work, whole exome sequencing (WES) identified the novel homozygous variant c.1217 T > G in ATAD3A, predicting a p.(Leu406Arg) substitution, in four siblings from a consanguineous family presenting with fatal neonatal cerebellar hypoplasia, seizures, axial hypotonia, hypertrophic cardiomyopathy, hepatomegaly, congenital cataract, and dysmorphic facies. Biochemical phenotypes of the patients included hyperlactatemia and hypocholesterolemia. Healthy siblings and parents were heterozygous for this variant, which is predicted to introduce a polar chain within the catalytic domain of ATAD3A that shortens its beta-sheet structure, presumably affecting protein stability. Accordingly, patient's fibroblasts with the homozygous variant displayed a specific reduction in ATAD3A protein levels associated with profound ultrastructural alterations of mitochondrial cristae and morphology. Our findings exclude the causative role of ATAD3B on this severe phenotype, expand the phenotypical spectrum of ATAD3A pathogenic variants and emphasize the vital role of ATAD3A in mitochondrial biogenesis.
Collapse
Affiliation(s)
- Susana Peralta
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain
| | - Adrián González-Quintana
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Marta Ybarra
- Servicio de Neonatología, Hospital Infantil La Paz, 28046 Madrid, Spain
| | - Aitor Delmiro
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Rafael Pérez-Pérez
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain
| | - Jorge Docampo
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Joaquín Arenas
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Alberto Blázquez
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Cristina Ugalde
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain.
| | - Miguel A Martín
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| |
Collapse
|
9
|
Serrano-Lorenzo P, Hidalgo I, González-Quintana A, Docampo J, Sánchez-Zapardiel J, Amate G, Delmiro A, Arenas J, Domínguez-González C, Blázquez-Encinar A, Martín M. P.62Muscle multiple mitochondrial DNA deletions: a genetic biomarker to detect nuclear-gene mutations in mtDNA maintenance disorders? Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
García Del Río A, Delmiro A, Martín MA, Cantalapiedra R, Carretero R, Durántez C, Menegotto F, Morán M, Serrano-Lorenzo P, De la Fuente MA, Orduña A, Simarro M. The Mitochondrial Isoform of FASTK Modulates Nonopsonic Phagocytosis of Bacteria by Macrophages via Regulation of Respiratory Complex I. J Immunol 2018; 201:2977-2985. [PMID: 30322967 DOI: 10.4049/jimmunol.1701075] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Accepted: 09/10/2018] [Indexed: 12/18/2022]
Abstract
Phagocytosis is a pivotal process by which innate immune cells eliminate bacteria. In this study, we explore novel regulatory mechanisms of phagocytosis driven by the mitochondria. Fas-activated serine/threonine kinase (FASTK) is an RNA-binding protein with two isoforms, one localized to the mitochondria (mitoFASTK) and the other isoform to cytosol and nucleus. The mitoFASTK isoform has been reported to be necessary for the biogenesis of the mitochondrial ND6 mRNA, which encodes an essential subunit of mitochondrial respiratory complex I (CI, NADH:ubiquinone oxidoreductase). This study investigates the role and the mechanisms of action of FASTK in phagocytosis. Macrophages from FASTK─/─ mice exhibited a marked increase in nonopsonic phagocytosis of bacteria. As expected, CI activity was specifically reduced by almost 50% in those cells. To explore if decreased CI activity could underlie the phagocytic phenotype, we tested the effect of CI inhibition on phagocytosis. Indeed, treatment with CI inhibitor rotenone or short hairpin RNAs against two CI subunits (NDUFS3 and NDUFS4) resulted in a marked increase in nonopsonic phagocytosis of bacteria. Importantly, re-expression of mitoFASTK in FASTK-depleted macrophages was sufficient to rescue the phagocytic phenotype. In addition, we also report that the decrease in CI activity in FASTK─/─ macrophages is associated with an increase in phosphorylation of the energy sensor AMP-activated protein kinase (AMPK) and that its inhibition using Compound C reverted the phagocytosis phenotype. Taken together, our results clearly demonstrate for the first time, to our knowledge, that mitoFASTK plays a negative regulatory role on nonopsonic phagocytosis of bacteria in macrophages through its action on CI activity.
Collapse
Affiliation(s)
| | - Aitor Delmiro
- Laboratorio de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación del Hospital 12 de Octubre, 28041 Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases, U723, 28029 Madrid, Spain
| | - Miguel Angel Martín
- Laboratorio de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación del Hospital 12 de Octubre, 28041 Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases, U723, 28029 Madrid, Spain
| | | | - Raquel Carretero
- Department of Microbiology, University of Valladolid, Valladolid, Spain
| | - Carlos Durántez
- Department of Microbiology, University of Valladolid, Valladolid, Spain
| | - Fabiola Menegotto
- Department of Microbiology, University of Valladolid, Valladolid, Spain
| | - María Morán
- Laboratorio de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación del Hospital 12 de Octubre, 28041 Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases, U723, 28029 Madrid, Spain
| | - Pablo Serrano-Lorenzo
- Laboratorio de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación del Hospital 12 de Octubre, 28041 Madrid, Spain
| | - Miguel Angel De la Fuente
- Department of Cell Biology, Histology and Pharmacology, University of Valladolid, 47005 Valladolid, Spain; .,Institute of Biology and Molecular Genetics, 47003 Valladolid, Spain
| | - Antonio Orduña
- Department of Microbiology, University of Valladolid, Valladolid, Spain.,Departamento de Microbiología e Inmunología, Hospital Clínico Universitario, 47003 Valladolid, Spain; and
| | - María Simarro
- Department of Nursing, University of Valladolid, 47005 Valladolid, Spain
| |
Collapse
|
11
|
Gallego-Bustos F, Gotea V, Ramos-Amador JT, Rodríguez-Pena R, Gil-Herrera J, Sastre A, Delmiro A, Rai G, Elnitski L, González-Granado LI, Allende LM. A Case of IL-7R Deficiency Caused by a Novel Synonymous Mutation and Implications for Mutation Screening in SCID Diagnosis. Front Immunol 2016; 7:443. [PMID: 27833609 PMCID: PMC5081475 DOI: 10.3389/fimmu.2016.00443] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Accepted: 10/07/2016] [Indexed: 12/04/2022] Open
Abstract
Reported synonymous substitutions are generally non-pathogenic, and rare pathogenic synonymous variants may be disregarded unless there is a high index of suspicion. In a case of IL7 receptor deficiency severe combined immunodeficiency (SCID), the relevance of a non-reported synonymous variant was only suspected through the use of additional in silico computational tools, which focused on the impact of mutations on gene splicing. The pathogenic nature of the variant was confirmed using experimental validation of the effect on mRNA splicing and IL7 pathway function. This case reinforces the need to use additional experimental methods to establish the functional impact of specific mutations, in particular for cases such as SCID where prompt diagnosis can greatly impact on diagnosis, treatment, and survival.
Collapse
Affiliation(s)
| | - Valer Gotea
- Translational and Functional Genomics Branch, National Human Genome Research Institute, NIH , Rockville, MD , USA
| | | | | | - Juana Gil-Herrera
- Servicio de Inmunología, Hospital Universitario e Instituto de Investigación Sanitaria Gregorio Marañón , Madrid , Spain
| | - Ana Sastre
- Servicio de Hematología Oncología, Hospital Universitario La Paz , Madrid , Spain
| | | | - Ghadi Rai
- GMGF, Aix-Marseille Université, Marseille, France; UMR_S 910, INSERM, Marseille, France
| | - Laura Elnitski
- Translational and Functional Genomics Branch, National Human Genome Research Institute, NIH , Rockville, MD , USA
| | - Luis I González-Granado
- Instituto de Investigación I+12, Madrid, Spain; Unidad de Inmunodeficiencias, Pediatría, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Luis M Allende
- Servicio de Inmunología, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación I+12, Madrid, Spain
| |
Collapse
|
12
|
Blázquez A, Domínguez-González C, Delmiro A, Rufián L, Martin-Santidrian M, Hernández-Laín A, Jiménez S, Serrano-Lorenzo P, González-Quintana A, Arenas J, Morán M, Martin M. Distinct myopathic phenotypes associated with two novel mutations at the anticodon stem pair 28T:42A of the MT-TN gene of the mtDNA. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Morán M, Blázquez A, Fiuza-Luces C, Díez-Bermejo J, Delmiro A, Docampo J, Serrano-Lorenzo P, González-Quintana A, Arenas J, Laín-Hernández A, Lucía A, Domínguez-González C, Martín M. Exercise intervention in a family with exercise intolerance and a novel mutation in the mitochondrial POLG gene. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Millan BS, Blazquez A, Delmiro A, Rufian L, Navarro C, Teijeira S, Martin M. Variable skeletal muscle involvement in VARS2 mitochondrial encephalomyopathy. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Yubero D, Montero R, Martín MA, Montoya J, Ribes A, Grazina M, Trevisson E, Rodriguez-Aguilera JC, Hargreaves IP, Salviati L, Navas P, Artuch R, Jou C, Jimenez-Mallebrera C, Nascimento A, Pérez-Dueñas B, Ortez C, Ramos F, Colomer J, O’Callaghan M, Pineda M, García-Cazorla A, Espinós C, Ruiz A, Macaya A, Marcé-Grau A, Garcia-Villoria J, Arias A, Emperador S, Ruiz-Pesini E, Lopez-Gallardo E, Neergheen V, Simões M, Diogo L, Blázquez A, González-Quintana A, Delmiro A, Domínguez-González C, Arenas J, García-Silva MT, Martín E, Quijada P, Hernández-Laín A, Morán M, Rivas Infante E, Ávila Polo R, Paradas Lópe C, Bautista Lorite J, Martínez Fernández EM, Cortés AB, Sánchez-Cuesta A, Cascajo MV, Alcázar M, Brea-Calvo G. Secondary coenzyme Q 10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. Mitochondrion 2016; 30:51-8. [DOI: 10.1016/j.mito.2016.06.007] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 05/06/2016] [Accepted: 06/29/2016] [Indexed: 11/30/2022]
|
16
|
Pérez-Pérez R, Lobo-Jarne T, Milenkovic D, Mourier A, Bratic A, García-Bartolomé A, Fernández-Vizarra E, Cadenas S, Delmiro A, García-Consuegra I, Arenas J, Martín MA, Larsson NG, Ugalde C. COX7A2L Is a Mitochondrial Complex III Binding Protein that Stabilizes the III2+IV Supercomplex without Affecting Respirasome Formation. Cell Rep 2016; 16:2387-98. [PMID: 27545886 DOI: 10.1016/j.celrep.2016.07.081] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 04/28/2016] [Accepted: 07/27/2016] [Indexed: 11/29/2022] Open
Abstract
Mitochondrial respiratory chain (MRC) complexes I, III, and IV associate into a variety of supramolecular structures known as supercomplexes and respirasomes. While COX7A2L was originally described as a supercomplex-specific factor responsible for the dynamic association of complex IV into these structures to adapt MRC function to metabolic variations, this role has been disputed. Here, we further examine the functional significance of COX7A2L in the structural organization of the mammalian respiratory chain. As in the mouse, human COX7A2L binds primarily to free mitochondrial complex III and, to a minor extent, to complex IV to specifically promote the stabilization of the III2+IV supercomplex without affecting respirasome formation. Furthermore, COX7A2L does not affect the biogenesis, stabilization, and function of the individual oxidative phosphorylation complexes. These data show that independent regulatory mechanisms for the biogenesis and turnover of different MRC supercomplex structures co-exist.
Collapse
Affiliation(s)
- Rafael Pérez-Pérez
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | - Teresa Lobo-Jarne
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | - Dusanka Milenkovic
- Department of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany
| | - Arnaud Mourier
- Department of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany
| | - Ana Bratic
- Department of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany
| | - Alberto García-Bartolomé
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | | | - Susana Cadenas
- Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM) and Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain; Instituto de Investigación Sanitaria Princesa (IIS-IP), 28006 Madrid, Spain
| | - Aitor Delmiro
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | - Inés García-Consuegra
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | - Joaquín Arenas
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | - Miguel A Martín
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain
| | - Nils-Göran Larsson
- Department of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden
| | - Cristina Ugalde
- Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid 28029, Spain.
| |
Collapse
|
17
|
Martín MÁ, García-Silva MT, Barcia G, Delmiro A, Rodríguez-García ME, Blázquez A, Francisco-Álvarez R, Martín-Hernández E, Quijada-Fraile P, Tejada-Palacios P, Arenas J, Santos C, Martínez-Azorín F. The homozygous R504C mutation in MTO1 gene is responsible for ONCE syndrome. Clin Genet 2016; 91:46-53. [PMID: 27256614 DOI: 10.1111/cge.12815] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Accepted: 05/31/2016] [Indexed: 01/31/2023]
Abstract
We report clinical and biochemical finding from three unrelated patients presenting ONCE (Optic Neuropathy, Cardiomyopathy and Encephalopathy with lactic acidosis and combined oxidative phosphorylation deficiency) syndrome. Whole-exome sequencing (WES) of the three patients and the healthy sister of one of them was used to identify the carry gene. Clinical and biochemical findings were used to filter variants, and molecular, in silico and genetic studies were performed to characterize the candidate variants. Mitochondrial DNA (mtDNA) defects involving mutations, deletions or depletion were discarded, whereas WES uncovered a double homozygous mutation in the MTO1 gene (NM_001123226:c.1510C>T, p.R504C, and c.1669G>A, p.V557M) in two of the patients and the homozygous mutation p.R504C in the other. Therefore, our data confirm p.R504C as pathogenic mutation responsible of ONCE syndrome, and p.V557M as a rare polymorphic variant.
Collapse
Affiliation(s)
- M Á Martín
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - M T García-Silva
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Unidad de Enfermedades Metabólicas Hereditarias, Hospital 12 de Octubre, Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - G Barcia
- Department of Genetics, Hôpital Necker-Enfants-Malades, Paris, France
| | - A Delmiro
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - M E Rodríguez-García
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - A Blázquez
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - R Francisco-Álvarez
- Universidad Francisco de Vitoria, Facultad de Ciencias Experimentales, Madrid, Spain
| | - E Martín-Hernández
- Unidad de Enfermedades Metabólicas Hereditarias, Hospital 12 de Octubre, Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - P Quijada-Fraile
- Unidad de Enfermedades Metabólicas Hereditarias, Hospital 12 de Octubre, Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | | | - J Arenas
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - C Santos
- Universidad Francisco de Vitoria, Facultad de Ciencias Experimentales, Madrid, Spain
| | - F Martínez-Azorín
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| |
Collapse
|
18
|
Hernández-Laín A, Guerrero AM, Domínguez-González C, Fernández-Vázquez I, Maya DG, Delmiro A, Arenas J, Morales JR, Blázquez A, Moran M, Martín MA. A novel RRM2B gene variant associated with Telbivudine-induced mitochondrial myopathy. J Neurol Sci 2015; 358:481-3. [PMID: 26359855 DOI: 10.1016/j.jns.2015.08.1550] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Revised: 08/29/2015] [Accepted: 08/31/2015] [Indexed: 11/26/2022]
Affiliation(s)
- Aurelio Hernández-Laín
- Department of Pathology (Neuropathology), Hospital Universitario 12 de Octubre, Madrid Research Institute, Spain.
| | | | - Cristina Domínguez-González
- Department of Neurology (Neuromuscular Unit), Hospital Universitario 12 de Octubre, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| | | | - David Gata Maya
- Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain.
| | - Aitor Delmiro
- Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| | - Joaquín Arenas
- Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| | - Juan Ruiz Morales
- Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain.
| | - Alberto Blázquez
- Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| | - María Moran
- Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| | - Miguel A Martín
- Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| |
Collapse
|
19
|
Mateos J, Landeira-Abia A, Fafián-Labora JA, Fernández-Pernas P, Lesende-Rodríguez I, Fernández-Puente P, Fernández-Moreno M, Delmiro A, Martín MA, Blanco FJ, Arufe MC. iTRAQ-based analysis of progerin expression reveals mitochondrial dysfunction, reactive oxygen species accumulation and altered proteostasis. Stem Cell Res Ther 2015; 6:119. [PMID: 26066325 PMCID: PMC4487579 DOI: 10.1186/s13287-015-0110-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 10/14/2014] [Accepted: 06/04/2015] [Indexed: 02/08/2023] Open
Abstract
INTRODUCTION Nuclear accumulation of a mutant form of the nuclear protein Lamin-A, called Progerin (PG) or Lamin AΔ50, occurs in Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeria, an accelerated aging disease. One of the main symptoms of this genetic disorder is a loss of sub-cutaneous fat due to a dramatic lipodystrophy. METHODS We stably induced the expression of human PG and GFP -Green Fluorescent Protein- as control in 3T3L1 cells using a lentiviral system to study the effect of PG expression in the differentiation capacity of this cell line, one of the most used adipogenic models. Quantitative proteomics (iTRAQ) was done to study the effect of the PG accumulation. Several of the modulated proteins were validated by immunoblotting and real-time PCR. Mitochondrial function was analyzed by measurement of a) the mitochondrial basal activity, b) the superoxide anion production and c) the individual efficiency of the different complex of the respiratory chain. RESULTS We found that over-expression PG by lentiviral gene delivery leads to a decrease in the proliferation rate and to defects in adipogenic capacity when compared to the control. Quantitative proteomics analysis showed 181 proteins significantly (p<0.05) modulated in PG-expressing preadipocytes. Mitochondrial function is impaired in PG-expressing cells. Specifically, we have detected an increase in the activity of the complex I and an overproduction of Superoxide anion. Incubation with Reactive Oxygen Species (ROS) scavenger agents drives to a decrease in autophagic proteolysis as revealed by LC3-II/LC3-I ratio. CONCLUSION PG expression in 3T3L1 cells promotes changes in several Biological Processes, including structure of cytoskeleton, lipid metabolism, calcium regulation, translation, protein folding and energy generation by the mitochondria. Our data strengthen the contribution of ROS accumulation to the premature aging phenotype and establish a link between mitochondrial dysfunction and loss of proteostasis in HGPS.
Collapse
Affiliation(s)
- Jesús Mateos
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Arancha Landeira-Abia
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Juan Antonio Fafián-Labora
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Pablo Fernández-Pernas
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
| | - Iván Lesende-Rodríguez
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Patricia Fernández-Puente
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Mercedes Fernández-Moreno
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
- Grupo de Genómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Aitor Delmiro
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i + 12), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, E-28041, Spain.
| | - Miguel A Martín
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i + 12), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, E-28041, Spain.
| | - Francisco J Blanco
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
| | - María C Arufe
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
| |
Collapse
|
20
|
Cámara Y, Carreño-Gago L, Martín MA, Melià MJ, Blázquez A, Delmiro A, Garrabou G, Morén C, Díaz-Manera J, Gallardo E, Bornstein B, López-Gallardo E, Hernández-Lain A, San Millán B, Cancho E, Rodríguez-Vico JS, Martí R, García-Arumí E. Severe TK2 enzyme activity deficiency in patients with mild forms of myopathy. Neurology 2015; 84:2286-8. [PMID: 25948719 DOI: 10.1212/wnl.0000000000001644] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 01/29/2015] [Indexed: 11/15/2022] Open
Affiliation(s)
- Yolanda Cámara
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain.
| | - Lidia Carreño-Gago
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Miguel A Martín
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Maria J Melià
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Alberto Blázquez
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Aitor Delmiro
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Gloria Garrabou
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Constanza Morén
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Jorge Díaz-Manera
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Eduard Gallardo
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Belén Bornstein
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Ester López-Gallardo
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Aurelio Hernández-Lain
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Beatriz San Millán
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Esther Cancho
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Jaime Samuel Rodríguez-Vico
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Ramon Martí
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| | - Elena García-Arumí
- From the Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (Y.C., L.C.-G., M.J.M., R.M., E.G.-A.) and Servei de Neurologia, Laboratori de Neurologia Experimental, Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP (E.G., J.D.-M.), Universitat Autònoma de Barcelona, Barcelona, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER) (Y.C., L.C.-G., M.A.M., M.J.M., A.B., A.D., G.G., C.M., J.D.-M., E.G., B.B., E.L.-G., R.M., E.G.-A.), Instituto de Salud Carlos III, Madrid, Spain; Laboratorio de Enfermedades Mitocondriales, (M.A.M., A.B., A.D.) and Sección de Neuropatología (A.H.-L.), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; Muscle Research and Mitochondrial Function Laboratory, Cellex-IDIBAPS, Faculty of Medicine (G.G., C.M.), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Biochemistry Unit (B.B.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Departamento de Bioquímica, Biologa Molecular y Celular (E.L.-G.), Universidad de Zaragoza, Zaragoza, Spain; Servicio de Anatomía Patológica (B.S.M.), Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Servicio de Neurología (E.C.), Hospital Don Benito Villanueva, Badajoz, Badajoz, Spain; Servicio de Neurología (J.S.R.-V.), Hospital Universitario de Burgos, Burgos, Spain
| |
Collapse
|
21
|
Castro-Gago M, Dacruz-Alvarez D, Pintos-Martínez E, Beiras-Iglesias A, Delmiro A, Arenas J, Martín MÁ, Martínez-Azorín F. Exome sequencing identifies a CHKB mutation in Spanish patient with megaconial congenital muscular dystrophy and mtDNA depletion. Eur J Paediatr Neurol 2014; 18:796-800. [PMID: 24997086 DOI: 10.1016/j.ejpn.2014.06.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 06/05/2014] [Accepted: 06/09/2014] [Indexed: 11/16/2022]
Abstract
BACKGROUND Choline kinase beta gene (CHKB) mutations have been identified in Megaconial Congenital Muscular Dystrophy (MDCMC) patients, but never in patients with an additional combined deficiency of complexes I, III and IV and mitochondrial DNA (mtDNA) depletion. AIMS To report mutations in carry genes for MDCMC with respiratory chain defects and mtDNA depletion. METHODS Whole-exome sequencing (WES) was used to identify the carry genes in a Spanish child with muscle weakness, mild hypotonia at lower limb muscles, mildly elevated creatine kinase (CK), enlarged mitochondria in the periphery of the fibers, combined deficiency of complex I, III and IV and depletion of mtDNA. RESULTS With WES data, it was possible to get the whole mtDNA sequencing and discard any pathogenic variant in this genome. The first filter of WES data with the nuclear-encoded mitochondrial genes (MitoCarta) did not get any candidate. However, the analysis of whole exome uncovered a homozygous nonsense pathogenic mutation in CHKB gene (NM_005198.4:c.810T>A, p.Tyr270*). CONCLUSIONS Our data confirm the role of CHKB in MDCMC and point to this gene as unique candidate for the combined deficiency of respiratory chain and mtDNA depletion observed in this patient.
Collapse
Affiliation(s)
- Manuel Castro-Gago
- Servicio de Neuropediatría, Departamento de Pediatría, Hospital Clínico Universitario, Facultad de Medicina, Santiago de Compostela, Spain
| | - David Dacruz-Alvarez
- Servicio de Neuropediatría, Departamento de Pediatría, Hospital Clínico Universitario, Facultad de Medicina, Santiago de Compostela, Spain
| | - Elena Pintos-Martínez
- Servicio de Anatomía Patológica, Hospital Clínico Universitario, Facultad de Medicina, Santiago de Compostela, Spain
| | - Andrés Beiras-Iglesias
- Servicio de Anatomía Patológica, Hospital Clínico Universitario, Facultad de Medicina, Santiago de Compostela, Spain
| | - Aitor Delmiro
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), E-28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, E-28041 Madrid, Spain
| | - Joaquín Arenas
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), E-28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, E-28041 Madrid, Spain
| | - Miguel Ángel Martín
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), E-28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, E-28041 Madrid, Spain
| | - Francisco Martínez-Azorín
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), E-28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, E-28041 Madrid, Spain.
| |
Collapse
|
22
|
Morán M, Delmiro A, Blázquez A, Ugalde C, Arenas J, Martín MA. Bulk autophagy, but not mitophagy, is increased in cellular model of mitochondrial disease. Biochim Biophys Acta 2014; 1842:1059-70. [PMID: 24704045 DOI: 10.1016/j.bbadis.2014.03.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 03/17/2014] [Accepted: 03/25/2014] [Indexed: 10/25/2022]
Abstract
Oxidative phosphorylation system (OXPHOS) deficiencies are rare diseases but constitute the most frequent inborn errors of metabolism. We analyzed the autophagy route in 11 skin fibroblast cultures derived from patients with well characterized and distinct OXPHOS defects. Mitochondrial membrane potential determination revealed a tendency to decrease in 5 patients' cells but reached statistical significance only in 2 of them. The remaining cells showed either no change or a slight increase in this parameter. Colocalization analysis of mitochondria and autophagosomes failed to show evidence of increased selective elimination of mitochondria but revealed more intense autophagosome staining in patients' fibroblasts compared with controls. Despite the absence of increased mitophagy, Parkin recruitment to mitochondria was detected in both controls' and patients' cells and was slightly higher in cells harboring complex I defects. Western blot analysis of the autophagosome marker LC3B, confirmed significantly higher levels of the protein bound to autophagosomes, LC3B-II, in patients' cells, suggesting an increased bulk autophagy in OXPHOS defective fibroblasts. Inhibition of lysosomal proteases caused significant accumulation of LC3B-II in control cells, whereas in patients' cells this phenomenon was less pronounced. Electron microscopy studies showed higher content of late autophagic vacuoles and lysosomes in OXPHOS defective cells, accompanied by higher levels of the lysosomal marker LAMP-1. Our findings suggest that in OXPHOS deficient fibroblasts autophagic flux could be partially hampered leading to an accumulation of autophagic vacuoles and lysosomes.
Collapse
Affiliation(s)
- María Morán
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain.
| | - Aitor Delmiro
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain
| | - Alberto Blázquez
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain
| | - Cristina Ugalde
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain
| | - Joaquín Arenas
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain
| | - Miguel A Martín
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain
| |
Collapse
|
23
|
Fiuza-Luces C, Delmiro A, Soares-Miranda L, González-Murillo Á, Martínez-Palacios J, Ramírez M, Lucia A, Morán M. Exercise training can induce cardiac autophagy at end-stage chronic conditions: insights from a graft-versus-host-disease mouse model. Brain Behav Immun 2014; 39:56-60. [PMID: 24239952 DOI: 10.1016/j.bbi.2013.11.007] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 11/03/2013] [Accepted: 11/07/2013] [Indexed: 11/30/2022] Open
Abstract
INTRODUCTION Chronic graft-versus-host disease (cGVHD) is a frequent cause of morbimortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and severely compromises patients' physical capacity. Despite the aggressive nature of the disease, aerobic exercise training can positively impact survival as well as clinical and functional parameters. We analyzed potential mechanisms underlying the recently reported cardiac function improvement in an exercise-trained cGVHD murine model receiving lethal total body irradiation and immunosuppressant treatment (Fiuza-Luces et al., 2013. Med Sci Sports Exerc 45, 1703-1711). We hypothesized that a cellular quality-control mechanism that is receiving growing attention in biomedicine, autophagy, was involved in such improvement. METHODS BALB/C female mice (aged 8wk) with cGVHD were randomly assigned to a control/exercise group (n=12/11); the exercise group underwent moderate-intensity treadmill training during 11wk after allo-HSCT. In the hearts of those few mice surviving the entire 11wk period (n=2/5), we studied molecular markers of: macroautophagy induction, preservation of contractile/structural proteins, oxidative capacity, oxidative stress, antioxidant defense, and mitochondrial dynamics. RESULTS Mainly, exercise training increased the myocardial content of the macroautophagy markers LC3BII, Atg12, SQSTM1/p62 and phospho-ULK1 (S555), as well as of α-tubuline, catalase and glutathione reductase (all p<0.05). CONCLUSIONS Our results suggest that exercise training elicits a positive autophagic adaptation in the myocardium that may help preserve cardiac function even at the end-stage of a devastating disease like cGVHD. These preliminary findings might provide new insights into the cardiac exercise benefits in chronic/debilitating conditions.
Collapse
Affiliation(s)
- Carmen Fiuza-Luces
- European University and Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain
| | - Aitor Delmiro
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain
| | - Luisa Soares-Miranda
- Research Centre in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, Portugal
| | | | | | - Manuel Ramírez
- Children's University Hospital Niño Jesús, Madrid, Spain
| | - Alejandro Lucia
- European University and Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain
| | - María Morán
- Mitochondrial and Neuromuscular Diseases Laboratory, Hospital Universitario 12 de Octubre Research Institute (i+12), Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain.
| |
Collapse
|
24
|
Fiuza-Luces C, Soares-Miranda L, González-Murillo A, Palacio JM, Colmenero I, Casco F, Melén GJ, Delmiro A, Morán M, Ramírez M, Lucia A. Exercise benefits in chronic graft versus host disease: a murine model study. Med Sci Sports Exerc 2014; 45:1703-11. [PMID: 23954992 DOI: 10.1249/mss.0b013e31828fa004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
INTRODUCTION Chronic graft versus host disease (cGVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation that generates considerable morbidity and compromises the physical capacity of patients. We determined the effects of an exercise training program performed after allogeneic hematopoietic stem cell transplantation on clinical and biological variables in a minor histocompatibility antigen-driven murine model of cGVHD treated with cyclosporine A. METHODS Recipient BALB/C female mice (age 8 wk) received bone marrow cells and splenocytes from donor B10.D2 male mice and were randomly assigned to an exercise (n = 11) or control group (n = 12). For approximately 11 wk after transplant, the exercise group completed a moderate-intensity treadmill program. Variables assessed were clinical severity scores, survival, physical fitness, cytokine profile, immune cell reconstitution, molecular markers of muscle exercise adaptations, and histological scores in affected tissues. RESULTS Exercise training increased survival (P = 0.011), diminished total clinical severity scores (P = 0.002), improved physical fitness (P = 0.030), and reduced blood IL-4 and tumor necrosis factor α levels (P = 0.03), while increasing circulating B220 (P = 0.008) and CD4 lymphocytes (P = 0.043). CONCLUSIONS A moderate-intensity exercise program that mimics widely accepted public health recommendations for physical activity in human adults was well tolerated and positive effects on survival as well as on clinical and biological indicators of cGVHD.
Collapse
Affiliation(s)
- Carmen Fiuza-Luces
- School of Doctorate Studies and Research, European University of Madrid, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Delmiro A, Rivera H, García-Silva MT, García-Consuegra I, Martín-Hernández E, Quijada-Fraile P, de Las Heras RS, Moreno-Izquierdo A, Martín MÁ, Arenas J, Martínez-Azorín F. Whole-exome sequencing identifies a variant of the mitochondrial MT-ND1 gene associated with epileptic encephalopathy: west syndrome evolving to Lennox-Gastaut syndrome. Hum Mutat 2013; 34:1623-7. [PMID: 24105702 DOI: 10.1002/humu.22445] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2013] [Accepted: 09/09/2013] [Indexed: 11/08/2022]
Abstract
We describe a West syndrome (WS) patient with unidentified etiology that evolved to Lennox-Gastaut syndrome. The mitochondrial respiratory chain of the patient showed a simple complex I deficiency in fibroblasts. Whole-exome sequencing (WES) uncovered two heterozygous mutations in NDUFV2 gene that were reassigned to a pseudogene. With the WES data, it was possible to obtain whole mitochondrial DNA sequencing and to identify a heteroplasmic variant in the MT-ND1 (MTND1) gene (m.3946G>A, p.E214K). The expression of the gene in patient fibroblasts was not affected but the protein level was significantly reduced, suggesting that protein stability was affected by this mutation. The lower protein level also affected assembly of complex I and supercomplexes (I/III2 /IV and I/III2 ), leading to complex I deficiency. While ATP levels at steady state under stress conditions were not affected, the amount of ROS produced by complex I was significantly increased.
Collapse
Affiliation(s)
- Aitor Delmiro
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, E-28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, E-28041, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Garcia-Consuegra I, Rubio J, Nogales G, Delmiro A, Blazquez A, Lucia A, Andreu A, Arenas J, Martin M. M.P.4.03 Transcript analysis for molecular characterization of “manifesting heterozygotes” patients with McArdle disease. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|